DUSP22 and cancer: Additionally, low expression of DUSP22 was significantly associated with various clinicopathological parameters, such as tumor stage, TNM cancer stage, and tumor grade (Fig. 1D and Table 1), suggesting that decreased DUSP22 expression could be a key factor in the initiation and advancement of LUAD.